GB0105360D0 - Chimaeric immunogens - Google Patents

Chimaeric immunogens

Info

Publication number
GB0105360D0
GB0105360D0 GBGB0105360.2A GB0105360A GB0105360D0 GB 0105360 D0 GB0105360 D0 GB 0105360D0 GB 0105360 A GB0105360 A GB 0105360A GB 0105360 D0 GB0105360 D0 GB 0105360D0
Authority
GB
United Kingdom
Prior art keywords
chimaeric
immunogens
chimaeric immunogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0105360.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0105360.2A priority Critical patent/GB0105360D0/en
Publication of GB0105360D0 publication Critical patent/GB0105360D0/en
Priority to EP02700490A priority patent/EP1368477A1/en
Priority to US10/469,561 priority patent/US20050260216A1/en
Priority to AU2002233560A priority patent/AU2002233560B2/en
Priority to NZ527873A priority patent/NZ527873A/en
Priority to CNA028093240A priority patent/CN1543504A/zh
Priority to CA002439628A priority patent/CA2439628A1/en
Priority to KR10-2003-7011573A priority patent/KR20030081490A/ko
Priority to MXPA03007915A priority patent/MXPA03007915A/es
Priority to BR0207819-8A priority patent/BR0207819A/pt
Priority to JP2002570736A priority patent/JP4238031B2/ja
Priority to CZ20032373A priority patent/CZ20032373A3/cs
Priority to IL15749802A priority patent/IL157498A0/xx
Priority to PCT/GB2002/000900 priority patent/WO2002070711A1/en
Priority to PL02365066A priority patent/PL365066A1/xx
Priority to HU0303372A priority patent/HUP0303372A3/hu
Priority to US10/233,902 priority patent/US20030194391A1/en
Priority to ZA200306647A priority patent/ZA200306647B/en
Priority to NO20033882A priority patent/NO20033882L/no
Priority to US11/041,636 priority patent/US20050186209A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0105360.2A 2001-03-03 2001-03-03 Chimaeric immunogens Ceased GB0105360D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB0105360.2A GB0105360D0 (en) 2001-03-03 2001-03-03 Chimaeric immunogens
HU0303372A HUP0303372A3 (en) 2001-03-03 2002-03-01 Vaccine
MXPA03007915A MXPA03007915A (es) 2001-03-03 2002-03-01 Vacuna.
JP2002570736A JP4238031B2 (ja) 2001-03-03 2002-03-01 ワクチン
AU2002233560A AU2002233560B2 (en) 2001-03-03 2002-03-01 Vaccine
NZ527873A NZ527873A (en) 2001-03-03 2002-03-01 Vaccine
CNA028093240A CN1543504A (zh) 2001-03-03 2002-03-01 疫苗
CA002439628A CA2439628A1 (en) 2001-03-03 2002-03-01 Vaccine
KR10-2003-7011573A KR20030081490A (ko) 2001-03-03 2002-03-01 백신
EP02700490A EP1368477A1 (en) 2001-03-03 2002-03-01 Vaccine
BR0207819-8A BR0207819A (pt) 2001-03-03 2002-03-01 Proteìna, citocina, il-13 humano mutado, polinucleotìdeo, vetor, hospedeiro, composição farmacêutica, uso de uma proteìna, métodos para o tratamento de profilaxia de doença mediada por il-13, e para a preparação de uma proteìna
US10/469,561 US20050260216A1 (en) 2001-03-03 2002-03-01 Vaccine
CZ20032373A CZ20032373A3 (cs) 2001-03-03 2002-03-01 Vakcinační prostředek
IL15749802A IL157498A0 (en) 2001-03-03 2002-03-01 Vaccine
PCT/GB2002/000900 WO2002070711A1 (en) 2001-03-03 2002-03-01 Vaccine
PL02365066A PL365066A1 (en) 2001-03-03 2002-03-01 Vaccine
US10/233,902 US20030194391A1 (en) 2001-03-03 2002-09-03 Vaccine
ZA200306647A ZA200306647B (en) 2001-03-03 2003-08-26 Vaccine.
NO20033882A NO20033882L (no) 2001-03-03 2003-09-02 Vaksine
US11/041,636 US20050186209A1 (en) 2001-03-03 2005-01-24 Vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0105360.2A GB0105360D0 (en) 2001-03-03 2001-03-03 Chimaeric immunogens

Publications (1)

Publication Number Publication Date
GB0105360D0 true GB0105360D0 (en) 2001-04-18

Family

ID=9909970

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0105360.2A Ceased GB0105360D0 (en) 2001-03-03 2001-03-03 Chimaeric immunogens

Country Status (18)

Country Link
US (3) US20050260216A1 (enExample)
EP (1) EP1368477A1 (enExample)
JP (1) JP4238031B2 (enExample)
KR (1) KR20030081490A (enExample)
CN (1) CN1543504A (enExample)
AU (1) AU2002233560B2 (enExample)
BR (1) BR0207819A (enExample)
CA (1) CA2439628A1 (enExample)
CZ (1) CZ20032373A3 (enExample)
GB (1) GB0105360D0 (enExample)
HU (1) HUP0303372A3 (enExample)
IL (1) IL157498A0 (enExample)
MX (1) MXPA03007915A (enExample)
NO (1) NO20033882L (enExample)
NZ (1) NZ527873A (enExample)
PL (1) PL365066A1 (enExample)
WO (1) WO2002070711A1 (enExample)
ZA (1) ZA200306647B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
CA2496409A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
JP2006501249A (ja) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
WO2004024183A1 (en) * 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
WO2004074432A2 (en) * 2003-01-31 2004-09-02 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
JP2007525436A (ja) * 2003-03-24 2007-09-06 マーシア・ファーマ・インコーポレイテッド 炎症症状を処置および予防するための方法および組成物
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1767216B1 (en) 2004-06-11 2012-07-11 Riken Drug having regulatory cell ligand contained in liposome
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090068195A1 (en) * 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
EP2155889A4 (en) * 2007-05-25 2010-06-16 Centocor Ortho Biotech Inc TOLL RECEPTOR 3 MODULATORS AND USES THEREOF
US8236318B2 (en) 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
AU2022215119A1 (en) * 2021-01-29 2023-08-17 Bayer Animal Health Gmbh Vaccine composition for breaking self-tolerance

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
CZ25697A3 (en) * 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
EP0815136B1 (en) * 1995-02-20 2007-06-13 The Walter And Eliza Hall Institute Of Medical Research Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
EP0759468A1 (en) * 1995-08-10 1997-02-26 Laboratoires Virbac Feline interleukin-4
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
EP0911401A1 (en) * 1997-10-21 1999-04-28 Bayer Ag Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain
AU758265B2 (en) * 1998-03-20 2003-03-20 Genzyme Corporation Induction of immunity against tumor self-antigens
US6576232B1 (en) * 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
WO2001034645A2 (en) * 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses

Also Published As

Publication number Publication date
PL365066A1 (en) 2004-12-27
EP1368477A1 (en) 2003-12-10
NO20033882L (no) 2003-10-31
CZ20032373A3 (cs) 2004-01-14
US20050260216A1 (en) 2005-11-24
US20030194391A1 (en) 2003-10-16
HUP0303372A3 (en) 2008-06-30
NO20033882D0 (no) 2003-09-02
HUP0303372A2 (hu) 2004-01-28
KR20030081490A (ko) 2003-10-17
NZ527873A (en) 2005-12-23
IL157498A0 (en) 2004-03-28
JP2005502314A (ja) 2005-01-27
BR0207819A (pt) 2004-03-02
WO2002070711A1 (en) 2002-09-12
AU2002233560B2 (en) 2006-09-07
US20050186209A1 (en) 2005-08-25
CN1543504A (zh) 2004-11-03
ZA200306647B (en) 2004-11-26
MXPA03007915A (es) 2003-12-04
JP4238031B2 (ja) 2009-03-11
CA2439628A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
HU0101106D0 (en) Id alsorithm
SI1671949T1 (sl) Substituirani pridinilamini
IL145461A0 (en) Inexuflator
EP1353546A4 (en) METHOD AND DEVICE FOR MONITORING PULSATION FOR TREATMENT DEVICE
PL362643A1 (en) Substituted fluoroalcoxyphenylsulfonylurea
AU2002359464A8 (en) Angiopioetin related factors
PT1406858E (pt) 4-aminociclo-hexanóis substituídos
DE50206483D1 (en) Displaymodul
HU0400176V0 (en) Improved gasketseal
PL364601A1 (en) Substituted benzo-nitro-heterocycles
GB0125464D0 (en) Burn-free
GB0111831D0 (en) Former
GB0007789D0 (en) Designing immunogens
GB2371467B (en) Girthing aid
CA92978S (en) Photo-changer
GB0102289D0 (en) Linkers
GB0113459D0 (en) Bubba bears
GB0117008D0 (en) Easy carry
GB0123728D0 (en) Connecting means
GB0110657D0 (en) Choice
TW569932U (en) Improved structure for heater
GB0126462D0 (en) Improved gyrocopter
TW505173U (en) Improved doorstopper
GB0123481D0 (en) Improved fancopter
GB0117866D0 (en) Cartenoid Expression

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)